Phase II US trial of liposomal docetaxel [ATI 1123] in gastric cancer

Trial Profile

Phase II US trial of liposomal docetaxel [ATI 1123] in gastric cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2017 This trial was being conducted by Azaya Therapeutics . The Company has now been acquired by Cytori Therapeutics, according to a Cytori Therapeuticsmedia release.
    • 18 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top